THERAVANCE BIOPHARMA INC (TBPH) Stock Price, Quote, News and Overview
NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD
TBPH Quote, Performance and Key Statistics
10.69
+0.08 (+0.75%)
The current stock price of TBPH is 10.69 USD. In the past month the price increased by 16.96%. In the past year, price increased by 26.06%.
TBPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.55 | 776.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.63 | 377.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 21.99 | 354.71B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.37 | 235.92B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.91 | 230.73B | ||
| MRK | MERCK & CO. INC. | 10.49 | 205.18B | ||
| PFE | PFIZER INC | 7.64 | 139.52B | ||
| SNY | SANOFI-ADR | 11.06 | 120.88B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.78 | 101.25B | ||
| GSK | GSK PLC-SPON ADR | 9.18 | 82.81B | ||
| ZTS | ZOETIS INC | 27.3 | 73.16B | ||
| HLN | HALEON PLC-ADR | 22.18 | 48.91B |
Related stock screener links
About TBPH
Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Company Info
THERAVANCE BIOPHARMA INC
Ugland House, South Church Street
GEORGE TOWN GRAND CAYMAN KY1-1104 KY
CEO: Rick E Winningham
Employees: 97
Phone: 16508086000
THERAVANCE BIOPHARMA INC / TBPH FAQ
What is the stock price of THERAVANCE BIOPHARMA INC today?
The current stock price of TBPH is 10.69 USD. The price increased by 0.75% in the last trading session.
What is the ticker symbol for THERAVANCE BIOPHARMA INC stock?
The exchange symbol of THERAVANCE BIOPHARMA INC is TBPH and it is listed on the Nasdaq exchange.
On which exchange is TBPH stock listed?
TBPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THERAVANCE BIOPHARMA INC stock?
10 analysts have analysed TBPH and the average price target is 15.56 USD. This implies a price increase of 45.51% is expected in the next year compared to the current price of 10.69. Check the THERAVANCE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THERAVANCE BIOPHARMA INC worth?
THERAVANCE BIOPHARMA INC (TBPH) has a market capitalization of 534.50M USD. This makes TBPH a Small Cap stock.
How many employees does THERAVANCE BIOPHARMA INC have?
THERAVANCE BIOPHARMA INC (TBPH) currently has 97 employees.
What are the support and resistance levels for THERAVANCE BIOPHARMA INC (TBPH) stock?
THERAVANCE BIOPHARMA INC (TBPH) has a support level at 10.6 and a resistance level at 11.26. Check the full technical report for a detailed analysis of TBPH support and resistance levels.
Is THERAVANCE BIOPHARMA INC (TBPH) expected to grow?
The Revenue of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 44.45% in the next year. Check the estimates tab for more information on the TBPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy THERAVANCE BIOPHARMA INC (TBPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TBPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TBPH, evaluating the profitability, health, valuation and growth aspects
- THERAVANCE BIOPHARMA INC (TBPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THERAVANCE BIOPHARMA INC (TBPH) Sales and EPS estimates to see what analysts future expectations are.
- THERAVANCE BIOPHARMA INC (TBPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THERAVANCE BIOPHARMA INC (TBPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- THERAVANCE BIOPHARMA INC (TBPH) Stock Chart to make your own analysis
- THERAVANCE BIOPHARMA INC (TBPH) Latest news and press-releases to stay up to date.
Does THERAVANCE BIOPHARMA INC (TBPH) stock pay dividends?
TBPH does not pay a dividend.
When does THERAVANCE BIOPHARMA INC (TBPH) report earnings?
THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of THERAVANCE BIOPHARMA INC (TBPH)?
THERAVANCE BIOPHARMA INC (TBPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).
What is the Short Interest ratio of THERAVANCE BIOPHARMA INC (TBPH) stock?
The outstanding short interest for THERAVANCE BIOPHARMA INC (TBPH) is 8.47% of its float. Check the ownership tab for more information on the TBPH short interest.
TBPH Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 86.14% of all stocks.
TBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TBPH. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TBPH Financial Highlights
Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS decreased by -30.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.98% | ||
| ROE | -35.14% | ||
| Debt/Equity | 0.19 |
TBPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to TBPH. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 68.74% and a revenue growth 44.45% for TBPH